Physician profile
Sarma Katrapati
NPI 1467485227
$4,277.07
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $551 · 2021: $1,064 · 2022: $992 · 2023: $993 · 2024: $67.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.04 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $396.70 | 2019-2023 | Farxiga |
| Glaxosmithkline, LLC. | $329.24 | 2021-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $320.06 | 2019-2023 | |
| Novo Nordisk INC | $299.83 | 2019-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $205.36 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.69 | 2019-2022 | |
| Amgen INC. | $152.04 | 2019-2022 | |
| Astellas Pharma US INC | $138.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $132.54 | 2019-2023 | |
| Alkermes, INC. | $120.19 | 2022-2023 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $118.71 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $118.06 | 2021-2022 | |
| Amarin Pharma, INC. | $116.88 | 2019-2021 | |
| Axsome Therapeutics, INC. | $115.63 | 2023 | Auvelity |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarma Katrapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.